<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147938</url>
  </required_header>
  <id_info>
    <org_study_id>FR-ADV-NI-003</org_study_id>
    <nct_id>NCT02147938</nct_id>
  </id_info>
  <brief_title>A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)</brief_title>
  <acronym>OPALE</acronym>
  <official_title>French Multicentre Observational Study of a Prospective Cohort of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment in a real situation of the conversion conditions, the efficacy and the safety of
      the treatment with tacrolimus in renal transplant patients converted from the tacrolimus
      twice per day form (Prograf®) to the tacrolimus once per day form (Advagraf®) with follow-up
      at one year.

      Analysis of two groups of patients: patients converted from Prograf® to Advagraf® early
      (during the first 6 months post-transplantation) or late (between 6 and 12 months
      post-transplantation).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2014</start_date>
  <completion_date type="Actual">May 15, 2017</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tacrolimus daily dose conversion ratio (mg Prograf® / mg Advagraf®)</measure>
    <time_frame>At baseline (i.e. time of conversion)</time_frame>
    <description>Percentage of patients with a tacrolimus dose conversion ratio of 1mg / 1mg and percentage of patients with a ratio ≠ 1mg / 1mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to measurement of the first trough tacrolimus blood concentration (C0) after conversion</measure>
    <time_frame>From baseline (conversion) to first determination of C0 assessed up to one year</time_frame>
    <description>number of days between the date of conversion and the date of first assay of C0 after conversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of additional visits that the doctor considers to be due to the conversion (if applicable)</measure>
    <time_frame>At 6 months and at 1 year follow-up visit</time_frame>
    <description>percentage of patients with additional visit(s) and percentage of patients without additional visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reasons for the conversion</measure>
    <time_frame>At baseline</time_frame>
    <description>number of capsules, poor treatment compliance, requested by patient, safety, centre practice, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of the patients in both groups</measure>
    <time_frame>At baseline</time_frame>
    <description>sociodemographic data, transplantation history, comorbidities, post-transplantation complications, risk factors and concomitant treatments (Immunosuppressive protocols (IS) and others) at the time of conversion and changes, if applicable, at 6 months and 1 year post-conversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach steady state</measure>
    <time_frame>Time from baseline (conversion) to steady state C0 assessed up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose ratio at steady state</measure>
    <time_frame>At baseline (conversion) and up to 6 months post-baseline</time_frame>
    <description>calculation of the tacrolimus daily dose ratio once the steady state is reached: mg Prograf® at conversion / mg Advagraf® once the steady state is reached. Percentage of patients with a ratio of 1mg / 1mg and percentage of patients with a ratio ≠ 1mg / 1mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The intra-patient variability (IPV) of tacrolimus</measure>
    <time_frame>At baseline and up to 6 months post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latest available laboratory data with Prograf® before conversion and with Advagraf®</measure>
    <time_frame>At baseline, 6 months and 1 year follow-up visit</time_frame>
    <description>Values and dates for blood and urine renal parameters, blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with the treatment at conversion and at 1 year post-conversion</measure>
    <time_frame>At baseline and 1 year follow-up visit</time_frame>
    <description>Compliance with the treatment at conversion (taking Prograf®) and at 1 year post-conversion (taking Advagraf®) only in group 2 (late conversion) will be assessed using the Morisky questionnaire, from which a score will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of life of the patient at conversion and at 1 year post-conversion</measure>
    <time_frame>At baseline and 1 year follow-up visit</time_frame>
    <description>The quality of life of the patient at conversion (taking Prograf®) and at 1 year post-conversion (taking Advagraf®) only in group 2 (late conversion) will be assessed using the EQ5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven acute rejections (BPAR) and survival of the graft and of the patient</measure>
    <time_frame>At 1 year follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects</measure>
    <time_frame>From baseline until 1 year follow-up visit after baseline (conversion)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">578</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>1: early conversion from Prograf® to Advagraf®</arm_group_label>
    <description>patients converted during the first 6 months post-transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: late conversion from Prograf® to Advagraf®</arm_group_label>
    <description>patients converted between 6 and 12 months post-transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>1: early conversion from Prograf® to Advagraf®</arm_group_label>
    <arm_group_label>2: late conversion from Prograf® to Advagraf®</arm_group_label>
    <other_name>Advagraf®</other_name>
    <other_name>Prograf®</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Renal transplant patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant patient for less than one year

          -  Patient where the conversion from Prograf® to Advagraf® has been decided by the doctor

        Exclusion Criteria:

          -  Patient participating in an interventional clinical trial at the time of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical and Scientific Affairs Manager, Transplantation</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma S.A.S.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Clermond-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Le Krémlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Lyon 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Paris 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>France</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>Observational</keyword>
  <keyword>Advagraf</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

